Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07361354 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS)
A Phase 1 study of Healthy Participants and Pharmacokinetic Study, sponsored by Angitia Incorporated Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07361354: Recruiting Phase 1 study of Healthy Participants and Pharmacokinetic Study, sponsored by Angitia Incorporated Limited.
NCT07361354 is a Phase 1 study of Healthy Participants and Pharmacokinetic Study that is actively recruiting participants, run by Angitia Incorporated Limited. The registered enrollment target is 30 participants, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07361354, a Phase 1 study of Healthy Participants and Pharmacokinetic Study, is actively recruiting participants, sponsored by Angitia Incorporated Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the effects of a single dose of AGA2118 in Japanese, Chinese, and Caucasian participants
Primary Outcome
Cmax of AGA2118 after dosing
Conditions Studied
Interventions
- DRUG AGA2118
Study Locations (1)
California
- Los Angeles EPCU - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-01-05 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
What NCT07361354 shows while recruiting
NCT07361354 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (54% lower).
The record links to 2 conditions, with Healthy Participants appearing as the primary indexed condition, and to 1 intervention - of which AGA2118 is the first listed.
NCT07361354 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07361354 about?
NCT07361354 is a clinical study titled "A Phase 1 Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS)". This study will evaluate the effects of a single dose of AGA2118 in Japanese, Chinese, and Caucasian participants
What is the current status of trial NCT07361354?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2026-01-05. Estimated completion is 2026-11.
What conditions does trial NCT07361354 study?
This clinical trial studies the following conditions: Healthy Participants, Pharmacokinetic Study.
What interventions are being tested in trial NCT07361354?
The interventions under investigation include: AGA2118 (DRUG).
Who is sponsoring clinical trial NCT07361354?
This trial is sponsored by Angitia Incorporated Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07361354 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07361354's enrollment target sits among peer trials
30 72nd of 119 higher than 45 of 119 other Healthy Participants trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Participants trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI